Brief: Guardant Health’S Infinityai Real-World Evidence Supports Approval Of Enhertu® For Previously Treated Patients With Her2-Positive Metastatic Solid Tumors In Japan
30/03/2026 15:11
March 30 (Reuters) - Guardant Health Inc GH.O: GUARDANT HEALTH’S INFINITYAI REAL-WORLD EVIDENCE SUPPORTS APPROVAL OF ENHERTU® FOR PREVIOUSLY TREATED PATIENTS WITH HER2-POSITIVE METASTATIC SOLID TUMORS IN JAPAN Source text: ID:nBw6RJ3tMa Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment